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Abstract: Age-associated cognitive decline and dementia are conditions in which there is deterioration in memory, 
thinking, and behavior, with profound effects on the ability to perform everyday activities and well-being. Even if 
dementia mainly affects older persons, it is not a normal part of aging. Alzheimer's disease accounts for 60–75% of 
dementia cases. The number of persons affected will increase in the next decades in parallel with aging of the world 
population. Hence, unless some approach is found to reduce age-related deterioration of cognitive functions, health 
care costs will continue to rise exponentially. There is a wealth of epidemiological evidence supporting a relation-
ship between diet and Alzheimer's disease, and suggesting that the risk of cognitive decline may be reduced by die-
tary interventions. It has been proposed that adopting a healthy diet and lifestyle that improves cardiovascular func-
tion may help delaying the onset of Alzheimer's disease due to its potential association with vascular disease. Sev-
eral nutrients, dietary components, supplements and dietary patterns have been reported in relation to their associa-
tion with cognition and with the development of cognitive decline and Alzheimer’s disease. The possible effect of diet on the prevention 
of dementia is of tremendous scientific and general interest, because hitherto there is no definitive evidence of any effective pharmacol-
ogical treatment for dementia. The aim of this review is to evaluate the evidence for the effects of some dietary components, supple-
ments, and dietary patterns as neuroprotective, with potential to delay cognitive decline and the onset of dementia.  
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1. INTRODUCTION 
 The cognitive decline that accompanies aging, as well as its 
extreme manifestation, dementia, are complex conditions with still 
not well defined causality. The number of persons affected will 
increase exponentially in the coming decades [1, 2] in parallel with 
aging of the world population [3], with remarkable finance and 
human burden, being dementia one of the greatest causes of disabil-
ity [2]. Worldwide, there are an estimated 47 million persons cur-
rently affected by dementia, and each year there are about 8 million 
newly diagnosed cases. Most of them, 60-75%, have Alzheimer’s 
disease (AD), with other major conditions including vascular de-
mentia and Lewy body dementia [1, 2]. These numbers imply an 
extraordinary burden on health care systems, families, caregivers 
and the individuals themselves. 
 Despite a large number of research on dementia and other neu-
rodegenerative diseases, the availability of effective interventions to 
significantly improve cognitive function is still some way off [4]. 
The hope for a cure for these debilitating diseases seems to repre-
sent a laudable mission, an admirable scientific achievement, but 
incredibly challenging, and if realized, is not likely to occur in the 
near future. 
 Nutrition and diet are key factors in the efficient clinical care of 
persons with cognitive decline of various grades, particularly in 
those experiencing dementia and AD [5]. Furthermore, the impact 
of diet and nutrition on cognitive function, and on the development 
of age-related cognitive decline is becoming a growing field, inso-
far as more data point to maximize the possible modifiable deter-
minants of these conditions [6, 7]. Understanding the complex in-
teractions among diverse dietary components, supplements, and 
dietary patterns with neurocognitive functions may embody oppor-
tunities to improve the knowledge of cognitive decline, dementia, 
and AD, and to influence outcomes. 
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 Diverse vitamins, minerals, and micronutrients have important 
potential antioxidant/anti-inflammatory and free-radical scavenging 
properties that may protect against brain oxidative damage, neu-
roinflammation, and consequent cognitive decline [8]. Most fatty 
acids in neuronal membranes are essential and must be obtained 
from the diet [9]. Fish oil, omega-3 fatty acids, eicosapentaenoic 
acid (EPA), and docosahexaenoic acid (DHA) may possess antioxi-
dant, anti-excitotoxic, and anti-inflammatory effects in brain tissue. 
DHA is one of the major building structures of membrane phos-
pholipids and it is necessary for normal neuronal function. It has 
been involved in neurotrophic, anti-apoptotic, and anti-inflam-
matory signaling [10]. Similar arguments may support the biologi-
cal plausibility of other specific supplements, but review of the 
clinical literature suggests that a plausible mechanism of action 
does not necessarily translate into significant benefits in normal 
aging adults or those with cognitive decline or dementia. Several 
dietary patterns have been studied in relation to their association 
with cognitive functions. Indeed, the evidence for benefit may de-
rive from synergistic interactions of different components put to-
gether in a food pattern [11].  
 In this review, we present the possible mediators and evidence 
for the effects of some dietary components, supplements, and die-
tary patterns as neuroprotective, with potential to delay cognitive 
decline and the onset of dementia.  
1.1. Possible Mediators and Associated Factors of the Effects of 
Diet and Supplements on Cognitive Decline and AD 
1.1.1. Oxidative Stress 
 Aging and age-related degenerative diseases, including neu-
rodegeneration, are characterized by a pro-oxidant, pro-
inflammatory state, which may contribute to their physiopathology, 
because of the harmful damage of free radicals on cellular compo-
nents. The brain is particularly susceptible to undergo oxidative 
damage. Cerebral metabolism requires high levels of energy, and it 
is closely dependent on aerobic conditions; it is also very rich in 
polyunsaturated fatty acids (PUFA), easily oxidizable, and in transi-
tion metals, likely to facilitate the formation of oxygen free radi-
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cals. Additionally, the brain has a low content of antioxidant sys-
tems compared to other tissues and organs in the body. Thus, the 
alteration of oxidative metabolism associated with old age might 
render the brain tissue prone to damage caused by the accumulation 
of neurotoxic peptides such as amyloid-beta [12]. Studies on post-
mortem brain tissue obtained from patients with AD have shown 
modifications of several oxidative damage markers, such as in-
creased lipid peroxidation, protein oxidative damage, glycol-
oxidation, and a reduction of antioxidant enzyme systems [13].  
1.1.2. Chronic Systemic Inflammation and Neuroinflammation 
 There is as well growing evidence suggesting that AD origins 
are associated with prominent neuroinflammation. Misfolded and 
aggregated proteins (e.g., amyloid) bind to microglia toll-like recep-
tors (TLRs) and CD4, generating an innate immune response with 
release of diverse inflammatory mediators. Systemic chronic low-
grade inflammation associated with obesity, aging and chronic dis-
eases, possibly alter immunological responses in the brain and fur-
ther enhance damage progression [14]. Even if microglia surround-
ing amyloid plaques and tangles were described in the original pub-
lication by Alois Alzheimer, only recently the role of neuroinflam-
mation in neurodegenerative disorders has been documented and 
explored. Neuroinflammation is key to protect central nervous sys-
tem; however, when uncontrolled and persistent, it eventually be-
comes destructive by the continuous release of reactive oxygen 
intermediates, cytokines, nitric oxide, proteolytic enzymes, com-
plementary factors, or excitatory amino acids [15]. Neuroinflamma-
tion itself may trigger accrual of amyloid-beta by increasing amy-
loid precursor protein (APP) levels. This has led to the proposed 
cascade hypothesis of AD, which states that amyloid-beta accumu-
lation induces neuroinflammation, which in turn generates more 
amyloid-beta, resulting in a vicious cycle and perpetuating damage 
[16]. Increased neuroinflammation has been reported in both mild 
cognitive impairment (MCI) and AD patients when compared with 
healthy controls using positron emission tomography and imaging 
with radioligand C-11-DAA1106 [17].  
 The innate immune response is classically characterized by pro-
inflammatory activation of macrophages with subsequent produc-
tion of specific cytokines, chemokines, and reactive oxygen species 
(M1); followed by resolution and alternative activation, in which 
macrophages undertake an anti-inflammatory phenotype (M2) in-
volved in wound repair and debris clearance. Even if there are still 
heterogeneous results, several investigators start to recognize the 
importance of microglia M1/M2 dynamics in diseases characterized 
by chronic neuroinflammation. It is suggested that amyloid-beta-
induced inflammatory environment in association with age-related 
effects on microglia, lead to a condition where M1 cells predomi-
nate and microglia lose the ability to switch phenotypes and miti-
gate damage [15]. Concerning nitric oxide (NO), its positive role as 
promoter of optimal cerebral blood flow at physiological concentra-
tions contrasts with the harmful effect of excessive NO production 
evoked by inflammatory signals, which have been identified as 
major players in the pathogenesis of neurodegenerative diseases. 
Disproportionate synthesis of NO under neuroinflammation leads to 
the release of reactive nitrogen species and neuronal death [18]. 
1.1.3. Prothrombotic State 
 Alzheimer’s disease is also characterized by vascular pathology 
(cerebrovascular dysfunction, decreased cerebral blood flow, and 
blood brain barrier [BBB] disruption, among others) and a 
prothrombotic state (increased clot formation, decreased fibrinoly-
sis, and activated platelets). Fibrinogen accumulates together with 
amyloid-beta and their binding promotes fibrinogen aggregation, 
amyloid-beta fibrillization, and formation of fibrin clots resistant to 
degradation. Decreasing fibrinogen not only reduces cerebral amy-
loid angiopathy and BBB altered permeability, but it also dimin-
ishes microglia activation and improves cognitive performance in 
AD mouse models [19]. In patients with AD, a recent study re-
ported higher platelet activating factor acetylhydrolase activity and 
higher oxidized-LDL levels when compared with control subjects 
[20].  
1.1.4. Obesity, Metabolic Syndrome, and Insulin Resistance 
 Compelling evidence indicates that risk factors for vascular 
atherosclerosis and for type 2 diabetes (T2D), either combined or in 
isolation, are also risk factors for the development of cognitive 
decline and AD [21]. “Metabolic syndrome” is the name given to 
clustering of risk factors (i.e., central obesity, hyperglycemia, hy-
pertension, atherogenic dyslipidemia, and a prothrombotic state), 
which is directly related to the accumulation of visceral adiposity in 
midlife linked to overeating and sedentary lifestyle with deleterious 
consequences in late-life, conceived by Morley as the “couch po-
tato” syndrome ]22]. The prevalence of MS is increasing [23], in 
parallel with the obesity epidemic [24]. Industrialization has facili-
tated the extensive availability of lots of inexpensive calorie-rich 
food together with a sedentary lifestyle, which paradoxically con-
tributed to the increased life expectancy in the last century. Exces-
sive nutrition has led to chronic non-communicable diseases com-
prising obesity, T2D, and cardiovascular disease (CVD) [24], which 
develop easily but are very difficult to treat. The health conse-
quences of over-nutrition are overwhelming and may become un-
sustainable. In addition, associations between obesity and impaired 
cognitive function, as well as greater risk of developing AD and 
other dementias, have more recently been recognized. Above and 
beyond the usual age-related cognitive decline, a growing body of 
evidence shows that both obesity and metabolic disorders in midlife 
are associated with poorer cognitive performance, cognitive de-
cline, and dementia in old age. A recent systematic review exam-
ined the results of twenty eight longitudinal studies conducted be-
tween 2003 and 2013 in three continents with follow-up from 5 to 
40 years. Most of the studies demonstrated and increased risk of 
late-onset dementia in midlife overweight and obese participants 
(up to 2.44 fold risk, with only three studies reporting no increased 
risk), providing a strong evidence for the association [25].  
 Even if the mechanism to explain this increase is still elusive, 
several possible mediators have been proposed. First, the obesity 
and overweight-related vascular comorbidities, such as hyperten-
sion, atherogenic dyslipidemia, or diabetes, are also risk factors for 
dementia [21]. However, most of multivariable analysis in the stud-
ies included these variables as potential confounder. Second, ele-
vated levels of plasma amyloid proteins have been found in obese 
persons [26], and the Framingham Offspring Cohort Study reported 
increased rates of hippocampal brain atrophy associated with mem-
ory and executive function decline with midlife obesity. In addition, 
a longitudinal study reported that being overweight or obese in 
midlife was associated with lower BBB integrity almost twenty five 
years later, possibly because of the chemical effects of a high-fat, 
high-sugar diet [27]. In rats, Western diet consumption produces 
increased permeability to a peripheral fluorescent tracer in the hip-
pocampus consequent to the BBB dysfunction [28]. 
 Third, a plausible mechanism intensively investigated in recent 
years is the accumulation and activation of macrophages in adipose 
tissue, which may trigger systemic and neuroinflammation. Adipose 
tissue can have immune cells and secrete pro-inflammatory cytoki-
nes [e.g., tumor necrosis factor (TNF), interleukin (IL)-1b, IL-6], 
which sustain low-grade chronic inflammation [29]. Obesity has 
been as well associated with a switch from M2 macrophages to the 
proinflammatory M1 phenotype [30]. A recent meta-analysis found 
that increased plasma levels of C-reactive protein and IL-6 are as-
sociated with an increased risk of dementia [31]. Dietary fats, in 
particular saturated fatty acids (SFA), induce inflammatory re-
sponses on microglia, leading to local cytokine production, involv-
ing often hypothalamic nuclear factor kappa B (NF-kB) activation, 
which may lead to apoptosis of key neurons involved in body 
weight control, central regulation of energy balance, glucose ho-
meostasis, and blood pressure [32, 33]. While the obesity-induced 
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activation of microglia in the hypothalamus is well-documented in 
animal models [34], there is also evidence of microglia activation in 
cognitive-related brains regions in obese db/db mice [35]. This 
hippocampal microglial activation was enhanced by 5-month ad-
ministration of a high-fat diet [36]. Obesity not only impacts brain 
function and structure in adults, but the most worrisome effect in-
volves modifications in the developing brain during childhood and 
adolescence [37], where the long-term negative consequences on 
the brain of a life-time being overweight are still unknown.  
 As opposed to over-nutrition, low-calorie diets, weight reduc-
tion or frequent consumption of food rich in antioxidant and anti-
inflammatory properties, or food patterns with combinations of 
them, have been associated with decreased markers of systemic and 
adipose tissue inflammation [38].  
 Diet studies in humans have shown a link between insulin resis-
tance and cognition [39], as well as T2D glucose regulation abnor-
malities and cognitive function [40]. Diet interventions that im-
proved insulin resistance have been associated with decreased in-
flammatory cytokines and improved cognition [41, 42].  
1.1.5. Autophagy 
 Autophagy is a catabolic process involved in recycling and 
degradation of cellular proteins, considered an adaptive response to 
the increased metabolic demand linked to nutrient starvation. Auto-
phagy efficiency declines with age, and growing evidence shows 
that enhanced autophagy delays aging and extends longevity, while 
reduced autophagy leads to premature aging. Autophagy is respon-
sible for the clearance of misfolded proteins, aggregates and the 
turnover of organelles within the neuron [43]. Evidence suggests 
that autophagy is deregulated in AD, suggesting that amyloid-beta 
accumulates in part due to impairment of autophagy degradation 
[44]. The mammalian target of rapamycin (mTOR), a conserved 
serine/threonine kinase, is involved in cellular senescence and age-
dependent diseases, as well as in cellular growth and metabolism in 
response to nutrients, growth factors and cellular energy conditions. 
There is evidence that mTOR signaling in the brain affects glucose 
metabolism, energy production, mitochondrial function and auto-
phagy [45]. All these events are crucial in age-related cognitive 
decline and AD. 
2. DIETARY COMPONENTS AND SUPPLEMENTS 
2.1. Vitamins 
 Results from the Physicians’ Health Study indicated that short-
term treatment with beta-carotene (provitamin A) had no significant 
effect on cognitive function, but that longer-term (18-year) admini-
stration was significantly superior to placebo in a cohort of 4,052 
participants [46].  
 Studies evaluating the impact of vitamin B on cognitive func-
tion have produced mixed results. A randomized controlled trial 
(RCT) of 299 men older than 75 years showed no significant effect 
of 2-year supplementation with folic acid, vitamin B6, and B12 
compared to placebo in improving cognitive function [47]. Like-
wise, a meta-analysis from 9 RCTs (n= 2,835 participants) cogni-
tively intact at baseline indicated no significant effect of folic acid 
with or without other B vitamins on cognitive function [48]. Con-
versely, an RCT of 900 persons with depressive symptoms aged 
60–74 years reported that a combination of folic acid and vitamin 
B12 was significantly superior to placebo for improving cognitive 
tests delivered by a validated telephone interview [49]. 
 Vitamins C and E are potent antioxidants, and their combined 
effects on cognitive function have been examined in numerous 
studies in healthy populations. These trials have produced conflict-
ing results. The Women’s Health Study including 6,377 women 
over65 years indicated no significant effect on cognitive function of 
vitamin E supplementation versus placebo [50]. Likewise, results 
from the analyses of 616 over65- year participants from the Duke 
Established Populations for Epidemiologic Studies showed that 
vitamins C and/or E supplements had no influence on the incidence 
of dementia or AD [51]. On the contrary, results from the Canadian 
Study of Health and Aging (n= 894 participants aged 65 years) 
indicated that a combination of vitamins C and E supplementation 
significantly decreased the rate of cognitive decline in this cohort 
[52]. A recent study analyzed the relations of alpha- and gamma-
tocopherol brain concentrations with AD neuropathology among 
115 deceased participants of the prospective Rush Memory and 
Aging Project. Gamma-tocopherol concentrations were associated 
with lower amyloid load and lower neurofibrillary tangle severity, 
while concentrations of alpha-tocopherol were not associated with 
neuropathology, except as modified by gamma-tocopherol: high 
alpha-tocopherol was associated with higher amyloid load when 
gamma-tocopherol levels were low and with lower amyloid levels 
when gamma-tocopherol levels were high. These results reflect the 
complexity of interconnections of subtypes of tocopherols and sug-
gest the use of gamma-tocopherol in RCTs [53]. 
 The Third National Health and Nutrition Examination Survey 
(NHANES III), a nationally representative cross-sectional study of 
the US noninstitutionalized population, reported that vitamin D 
deficiency was associated with an increased risk of cognitive de-
cline [54]. Conversely, results from the Women’s Health Initiative 
showed no significant effect of vitamin D and calcium supplemen-
tation on cognitive function in 2,034 women older than 65 years, 
followed for a mean of 7.8 years [55]. 
 Large clinical trials of multivitamins supplementation have 
indicated no significant effects on cognitive function in healthy 
adults. Results from the Age-Related Eye Disease Study that in-
cluded 2,166 subjects followed for 6.9 years showed that a combi-
nation of antioxidant vitamins (vitamin E, vitamin C, and beta-
carotene), zinc, and copper had no significant effects on any of six 
tests of cognitive function [56]. Similarly, the Women’s Antioxi-
dant Cardiovascular Study that included 2,824 women with or at 
risk for CVD who received a combination of vitamin E, beta-
carotene, and vitamin C or placebo indicated that the multivitamin 
supplementation did not alter cognitive function [57]. 
2.2. Omega-3 Fatty Acids  
 Polyunsaturated fatty acids are key components of neuronal cell 
membranes, preserving membrane fluidity that is essential for syn-
aptic vesicle fusion and neurotransmitter communication within 
neural networks. Membrane PUFAs also serve as precursors for 
lipid messengers, which can participate in signaling processes to 
promote neuroprotection or induce neuronal failure [58]. Some 
studies have reported a deficit of PUFAs in the aged brain located 
in the hippocampus, cortex, and cerebellum, all areas implicated in 
cognitive and motor functions [59-61]. These deficits may be worse 
in AD. 
 Among PUFA, omega-3 fatty acids are the most studied com-
pounds regarding cognitive decline. As with other dietary compo-
nents, there are dissimilar results for omega-3 supplementation. A 
systematic literature review showed that existing data favor a role 
for long-chain omega-3 fatty acids in reducing cognitive decline in 
older persons without dementia [62]. Nevertheless, several studies 
not included in this review have shown no significant effect of 
omega-3 fatty acids on cognitive decline. Results from 1,748 par-
ticipants with a history of cardio- or cerebrovascular disease of the 
Supplementation with Folate, vitamin B6 and B12 and/or OMega-3 
fatty acids trial reported no significant effects of vitamin B and 
omega-3 fatty acid supplementation on cognitive function [63]. A 
double-blind, placebo-controlled trial involving 302 cognitively 
intact persons older than 65 years who were randomly assigned to 
1,800 mg/day EPA-DHA, 400 mg/day EPA-DHA, or placebo for 
26 weeks indicated no significant differential changes in any of the 
cognitive domains evaluated for either dose supplementation com-
pared with placebo [64, 65]. However, the relatively short duration 
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of this trial may have precluded observation of a benefit of EPA-
DHA. Findings from a more recent meta-analysis that included 
results from 3,536 persons older than 60 years without cognitive 
dysfunction at baseline reported no significant effect on cognitive 
function of omega-3 fatty supplementation [66]. In a recent epide-
miological study among Chinese adults, age significantly modified 
the association between fish consumption and cognitive change. In 
persons aged 65 years and older who consumed 1 serving/week 
(i.e., 100 g) of fish, the mean annual rate of global cognitive decline 
was reduced by 0.35 point (95% CI: 0.13, 0.58). Fish consumption 
was also associated with a slower decline in composite and verbal 
memory scores. No associations were observed among adults aged 
55-64 years [67].  
2.3. Magnesium 
 Several studies have shown convincingly that magnesium (Mg) 
deficiency results in increased production of oxygen-derived free 
radicals in various tissues, increased free-radical-elicited oxidative 
tissue damage, increased production of superoxide anion by in-
flammatory cells, decreased antioxidant enzyme expression and 
activity, decreased cellular and tissue antioxidant levels, and in-
creased oxygen peroxide production [68-71]. Physiological concen-
trations of Mg are essential for synaptic conduction and are re-
quired for normal functioning of the nervous system. Mg exerts 
various actions on neuronal functions via different pathways. The 
concentration of Mg affects many biochemical mechanisms, which 
consist of N-methyl-D-aspartate (NMDA) receptor response to 
excitatory amino acids [72], inhibition of calcium channels, calcium 
influx, and glutamate release, and effects on the stability and vis-
cosity of the cell membrane [73]. The toxic effects of calcium in 
excitable cells are influenced by intracellular levels of Mg [74]. Mg 
is a physiological calcium antagonist, and this action may contrib-
ute to its neuroprotective properties. Because Mg ion modulates 
vascular tone by affecting calcium ion concentrations, Mg deficit 
produces vasospasm while elevated Mg causes tone relaxation in 
cerebral arteries [75]. These mechanisms have important roles in 
chronic neuronal degeneration and subsequent development of de-
mentia. Hence, the role of Mg in dementia and other degenerative 
disorders has been the focus of increased attention in recent years. 
Several alterations of Mg metabolism have been found in AD pa-
tients. Previous studies have shown decreased serum Mg values in 
patients with severe AD [76]. We have described a reduction of the 
active ionized free Mg concentrations (Mg ion) in plasma obtained 
from AD patients [77], with Mg-ion levels significantly related to 
cognitive dysfunction severity. Cilliler et al. [78] also found a nega-
tive correlation between serum Mg levels in AD patients with the 
Global Deterioration Scale and the Clinical Dementia Rating, fur-
ther confirming a possible protective role of Mg, and/or a negative 
impact of Mg deficits on cognitive function. Brain tissue from 
autopsies of AD patients has lower Mg concentrations [79]. Al-
though there are no specific trials with Mg supplements in the pre-
vention or therapy of cognitive disorders, interestingly, treatment of 
dementia patients with nutritional Mg support has been suggested to 
improve memory and other symptoms [80]. Given the prevalence of 
Mg inadequacy in the aging population, Mg supplementation may 
be of potential help in the prevention and treatment of dementia. 
However, whether Mg supplementation may exert protective effects 
against AD remains to be further elucidated in well-design trials 
[81]. 
2.4. Curcuminoids 
 Curcumin is a polyphenolic compound derived from the rhi-
zome of the Curcuma longa. It is contained in culinary curry spice 
turmeric and used as a coloring agent in food. Traditional Indian 
medicine considered this compound as an effective therapy for 
several pathological conditions, ranging from asthma to epilepsy, 
from gallstone to diabetic wound healing [82]. The potential role of 
curcumin in dementia originates from an epidemiological study in 
2000 by Ganguli et al. [83] reporting a lower prevalence of AD in 
the Indian population, who consumes a diet rich in curcumin-
containing curry, compared to the US population. Afterwards, Ng et 
al. [84] found that older healthy persons who consume more fre-
quently curry show a better cognitive performance. Based on these 
preliminary observations, numerous experimental studies were 
conducted confirming the potent anti-oxidant and anti-
inflammatory properties of curcumin and its protection on AD ani-
mal models. In humans, curcumin seems to have a good safety pro-
file in cancer patients (using doses from 500 to 8000 mg/day for 
three months) [85]. Concerning cognitive decline, three RCTs have 
been so far completed. In 2008, Baum et al. [86] performed a RCT 
enrolling 34 patients with AD, randomized to receive either curcu-
min at two different doses (1 g/day or 4 g/day) or placebo (4 g/day) 
for six months. All subjects also received 120 mg/day of standard-
ized gingko biloba leaf extract without modifications in previous 
medications. There was no significant difference between curcumin 
treatment and placebo in Mini Mental State Examination (MMSE), 
with no serious side effects reported. Another RCT was reported in 
2012 by Ringman et al. [87], recruiting 36 patients with dementia 
who randomly received 2 g/day or 4 g/day of Curcumin C3 Com-
plex (95% of curcuminoids) in two divided doses or placebo for 24 
weeks. The trial was extended to 48 weeks as an open-label trial in 
which patients who received placebo were randomly assigned to 2 
g/day or 4 g/day of Curcumin C3 Complex, while patients on 
treatment continued with the same dose assigned at baseline. Pri-
mary outcomes were changes at the AD Assessment Scale, cogni-
tive sub-portion (ADAS-Cog) at 24 weeks, and tolerability at 48 
weeks. Secondary outcome measures were change at the Neuropsy-
chiatric Inventory (NPI), the AD Cooperative Study Activities of 
Daily Living (ADCS-ADL), and the MMSE, and modification in 
plasma and cerebrospinal fluid (CSF) markers. The authors did not 
observe any significant difference between treatment groups in any 
of the scores or CSF markers. No serious adverse event was re-
ported. Plasma levels of curcumin were undetectable after single 
doses, consistent with the low bioavailability of oral curcumin. In 
2012, Hishikawa et al. [88] reported a case study of three dementia 
patients treated with 100 mg/day of curcumin. All three patients 
experienced a decreased in NPI scores (with reduction in agitation, 
irritability, anxiety, and apathy) after 12 weeks of therapy. One 
patient with moderate cognitive decline (12/30 on MMSE) im-
proved his MMSE score by five points. All patients were on anti-
dementia medication (donepezil) before starting curcumin. As men-
tioned, a major obstacle with curcumin in clinical studies has been 
the limited bioavailability of supplements, but this problem has 
been solved with new lipidated formulations [89].  
 In conclusion, to date there is insufficient evidence to suggest 
the use of curcumin in dementia patients. There are several ongoing 
clinical trials evaluating the efficacy of curcumin in AD or MCI, 
which hopefully will shade more light on the potential therapeutic 
efficacy of curcumin in dementia. 
2.5. Gingko biloba 
 An RCT including 3,069 participants randomized into G. biloba 
treatment or placebo to determine whether G. biloba supplementa-
tion could prevent dementia among older adults who were cogni-
tively intact or had MCI at baseline. Participants were followed for 
a median of 6.1 years, and the study results indicated no difference 
in the rate of cognitive decline for the two treatment groups [90]. 
2.6. Acetyl-L-Carnitine  
 Neuroprotective effects of acetyl-L-carnitine (ALCAR) have 
been shown in vitro [91], and its effects on cognitive function have 
been evaluated in several small studies. Results from an RCT of 66 
persons aged over 100 years indicated that ALCAR significantly 
improved MMSE scores compared to placebo [92]. A second small-
scale study that included 96 adults older than 70 years indicated that 
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ALCAR supplementation resulted in significant improvements in 
MMSE scores versus placebo [93]. 
2.7. Phytoestrogen Compounds  
 Soy isoflavones are a group of phytoestrogen compounds, 
which have been studied seeking alternatives to estrogen treat-
ments. In general, the studies have used mixtures of isoflavones, 
including genistein and daidzein, making it difficult to discern the 
effects of specific components of soy phytoestrogen diets on cogni-
tion. Studies in cells and animals have shown to reduce AD pathol-
ogy, and have demonstrated antioxidant properties. However, in-
vestigations of soy consumption and phytoestrogen supplements on 
cognitive function in humans have reported variable and inconclu-
sive results [94].Overall, there is absence of endometrial thickness, 
circulating hormone concentrations alterations or other important 
adverse events [95]. Like for hormone replacement therapy, there 
seems to be and age-dependent effect of phytoestrogen supplements 
in post-menopausal women (i.e., initial positive cognitive effects, 
which reverse in elderly women), but this is not addressed by clini-
cal trials; while in men the data are scarce and even more equivocal 
[94]. Possible reasons to help explain the discrepancies include the 
use of different isoflavone supplements, at dissimilar doses, and the 
fact that most are small short-term trials. Importantly, studies re-
porting no effect of phytoestrogens on cognition have been mostly 
performed in European cohorts, with low dietary consumption of 
soy products. Conversely, studies of older Asian populations, with 
higher consumption of soy-derived foods have shown inverse asso-
ciations with cognitive decline [94]. S-equol is a selective estrogen 
receptor (ER)-beta agonist with lower binding activity for ER-alpha 
(predominantly expressed in the breast and uterus). ER-beta is 
highly expressed in hippocampal neurons [96]. After oral admini-
stration of conjugated isoflavones, daidzein is converted to S-equol 
by a gut biotransformation. It has been shown that about 70% of 
older Japanese persons are “equol producers” [97], which may help 
explain the different results in Asian vs. Europeans participants. 
Importantly, in most studies the S-equol producer status was not 
established. 
 To overcome some of the limitations in earlier studies, the 
Women’s Isoflavone Soy Health (WISH) trial was performed [98], 
in which 313 postmenopausal women aged 45-92 years were ran-
domized to receive a daily oral dose of 25 g of isoflavone-rich soy 
protein (containing genistein, daidzein, and glycitein) or milk pro-
tein-matched placebo. The dose was comparable to that of tradi-
tional Asian diets. Cognitive function was evaluated at baseline and 
after 2.5 years with the changes in a composite score based on 14 
neuropsychological tests. There was no significant difference be-
tween the groups in cognition changes from baseline. However, 
women within 5-10 years of menopause in the isoflavone group 
showed a nonsignificant (p=0.07) trend toward cognitive improve-
ment, and a significant improvement in verbal episodic memory. 
Urinary S-equol was determined and women classified as non- or 
intermediate-producers did not have any changes in cognition. 
Conversely, consistent producers showed a nonsignificant (p=0.08) 
trend toward cognitive improvement. However, further studies are 
needed to confirm these findings. There are no clinical trials of 
phytoestrogens for the treatment or prevention of AD.  
2.8. Tea and (-)-Epigallocatechin-3-gallate (EGCG) 
 In Asian cultures, tea is traditionally view as a natural cognitive 
stimulator or nootropic because it helps maintain alertness and con-
centration. This acute effect has been confirmed in controlled stud-
ies, as shown in the review by Einother and Martens [99]. Based on 
these observations, it has been proposed that regular tea drinking 
may also exert benefits on cognitive performance in the long-term 
[100]. Tea contains diverse bioactive compounds, such as EGCG, 
L-theanine, and caffeine, which have antioxidant and anti-
inflammatory properties that may be neuroprotective [100, 101]. 
Other biological mechanisms by which tea may exert neuroprotec-
tive actions include regulation and production of stress hormones, 
inhibition of acetylcholinesterase, and regulation of brain neuro-
transmitter systems [101]. Although currently numerous studies 
suggests that tea consumption has protective actions on cognitive 
performance in late life, no definitive conclusion can be drawn 
given the inconsistent findings currently available [102]. More pro-
spective studies are needed perhaps using objective biomarkers of 
tea intake [103]. Bioactive compounds, such as EGCG and L-
theanine, may have some potential due to their antioxidant proper-
ties and anti-amyloidogenic activity in vitro. Nevertheless, the evi-
dence for their use as drugs or medical food is limited [104] and 
there is no current recommendation for using this compounds in the 
clinical or public health practice. 
2.9. Resveratrol 
 The phytoalexin resveratrol is a polyphenol contained in ber-
ries, with the highest source of dietary resveratrol in humans being 
grapes and red wine [105]. In the past decade, a number of biologi-
cal properties of resveratrol have been reported, including antioxi-
dant and anti-inflammatory actions [106]. Initially, effects of res-
veratrol on CVD and cancer were explored, and lately the potential 
of resveratrol as a neuroprotective compound has been investigated. 
Even if there are studies in animal models of AD showing that res-
veratrol administration was associated with, for example, reduced 
hippocampal neurodegeneration [107], and increased spatial mem-
ory performance in non-human primates [108], human clinical trials 
evaluating the effects of resveratrol on neurodegenerative diseases 
are currently limited. One placebo-control study in 22 healthy 
adults showed a dose-dependent (250-500 mg/day) increase in 
cerebral blood flow in the prefrontral cortex during cognitive tasks 
[109]. If these findings are confirmed, this may be an area in which 
resveratrol possibly have potential clinical benefits. Another study 
evaluated 23 overweight persons, aged 50-75 years, receiving res-
veratrol (200 mg/d) for 26 weeks vs. a group receiving placebo, 
reporting an improved memory performance and higher functional 
connectivity of the hippocampus in neuroimaging assessment with 
resveratrol treatment [110]. There are currently several ongoing 
clinical trials on resveratrol investigating its potential therapeutic 
effects on cognitive function in the aging brain, as well as in MCI 
and AD [111]. At present, there is no substantial data on toxicity of 
chronic resveratrol supplementation, although ongoing trials possi-
bly will address this concern.  
 In summary, there is no sufficiently substantiated support cur-
rently for prescribing resveratrol supplements to improve cognitive 
function in healthy persons or patients with MCI or AD. More stud-
ies are still needed to clarify the possible effects, toxicity, and un-
derlying mechanisms of potential neuroprotective effects of res-
veratrol.  
2.10. Garlic (Allium sativum) 
 Extracts of garlic and some of its components have shown to 
exert antioxidant actions and to protect against amyloid-beta-
induced neurotoxicity in cells and in experimental animals [112, 
113]. Allicin, an organosulfur compound obtained from garlic, has 
been shown to inhibit cholinesterase enzymes and upregulate levels 
of acetylcholine in the brain [114], suggesting a potential use in the 
treatment of AD. However, currently there is no evidence from 
clinical trials involving patients for any beneficial effects of these 
compounds. In the Doetinchem Cohort Study, in which 2613 par-
ticipants aged 43-70 years were examined for cognitive function 
with a 5-year interval and dietary assessment was performed, higher 
consumption of allium (onion, garlic, and leek) was associated with 
worse scores on speed of cognitive processes and cognitive flexibil-
ity in cross-sectional analyses. On the contrary, in longitudinal 
analyses, allium consumption was not associated with cognitive 
decline [115].  
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2.11. Caffeine 
 The xanthine alkaloid caffeine has been shown to possess anti-
oxidative properties, via quenching of hydroxyl radicals [116], and 
to decrease amyloid-beta production in animal models of AD [117]. 
The reduction in amyloid-plaques was associated with a stimulation 
of protein kinase A activity, increased phosphor-CREB levels, and 
reduced phosphor-JNK and phosphor-ERK expression in mouse 
models of AD [117, 118]. These data suggest that caffeine inhibits 
proapoptotic pathways and promotes prosurvival cascades in the 
brain [118]. 
  While coffee and caffeine are recognized to strengthen short-
term memory and cognition, limited research also suggests that 
long-term use may protect against cognitive decline or dementia. 
Some studies have shown that caffeine consumption is associated 
with better cognitive performance and with a slower cognitive de-
cline [117, 119]. A case-control study among 124 older persons 
showed that high blood levels of caffeine (1200 ng/mL) were linked 
with lack of progression to dementia in patients with MCI [120]. 
Another study reported a 65% decrease in incident AD and demen-
tia in persons who had a consumption of 3 to 5 cups of coffee per 
day [121]. A study among 3,494 men in the Honolulu-Asia Aging 
Study assessing neuropathologic parameters of dementia, reported 
that deceased men in the highest quartile of caffeine intake were 
less likely to have any lesion type when compared to men in the 
lowest quartile. Nevertheless, coffee and caffeine intake in midlife 
were not associated with risk of cognitive impairment, overall de-
mentia, AD, vascular dementia, or moderate/high levels of individ-
ual neuropathologic lesion types [122].  
 A meta-analysis of studies exploring the relationship of caffeine 
consumption and cognitive decline reported a nonsignificant effect 
[123], but the large heterogeneity across the few number of studies 
included precluded definitive statements on this topic. Caffeine 
consumption was associated with slower cognitive decline among 
older people in Portugal [124]; while no associations were found in 
a study of men and women from France [125], and in another study 
from Finland [126]. A longitudinal study of cognitive decline and 
coffee consumption reported less decline among coffee consumers 
in women but not in men, and there was no dose response [127]. 
These findings are similar to those from studies of coffee and de-
mentia showing significance but without demonstrating a dose-
response relationship [119, 121]. 
 In summary, coffee intake has been associated with a lower risk 
of dementia and cognitive impairment in some, but not all, studies. 
There is hitherto no evidence from RCTs. The heterogeneity of the 
available evidence (i.e., timing of exposure, confounding, survival 
bias owing to the cohort age) precludes definitive conclusions re-
garding the role of coffee in the prevention of dementia. Further 
studies are needed in order to clarify the role of coffee in the devel-
opment of cognitive impairment and dementia. 
3. DIETARY PATTERNS 
 Dietary patterns in populations of diverse culture, ethnicity, or 
religious beliefs have been assessed in relation to chronic diseases 
including atherosclerosis, hypertension, diabetes, and, more re-
cently, dementia and AD. There are various reviews on the numer-
ous epidemiological studies supporting a relationship between diet 
and AD [128-131], suggesting that the risk of cognitive decline may 
be modified by dietary interventions. There is no single dietary or 
lifestyle intervention definitively proven in RCTs to prevent inci-
dent AD. However, epidemiological data suggest that adopting a 
healthy, balanced diet and lifestyle that improves cardiovascular 
risk may help delay the onset of AD due to the potential contribu-
tion of vascular disease to dementia [132]. Considering a dietary 
pattern based on healthy policy guidelines, the Healthy Eating In-
dex-2005 (HEI-2005) (Dietary Guidelines for Americans), two 
cross-sectional studies [133, 134] showed an association between a  
 
HEI-2005 and improvements in cognition in five of the six cohorts 
assessed. However, two of the longitudinal studies [135, 136] fol-
lowed up to 7.6 years showed no association between HEI-2005 
and cognition. Conversely, the study by Wengreen et al. [137], with 
an 11-year follow-up showed less cognitive decline with an in-
creased HEI score, suggesting that a longer duration may be re-
quired to disclose the effect of diet on cognition.  
3.1. Mediterranean Diet 
 The Mediterranean diet (MeDiet), a dietary pattern largely con-
sumed among the populations bordering the Mediterranean Sea 
since millennia, has been widely reported as a model of healthy 
eating for its contribution to a favorable health status and quality of 
life. The MeDiet is characterized by high intake of vegetables, leg-
umes, fruits, and cereals; extravirgin olive oil as the main source of 
fat; low intake of saturated fatty acids; moderately high intake of 
fish; low to moderate intake of dairy products (mostly cheese or 
yogurt); low intake of meat and poultry; and regular but moderate 
intake of alcohol, primarily in the form of red wine and generally 
during meals [138]. There is not a single Mediterranean dietary 
pattern because dietary traditions differ between cultures and coun-
tries, hence, a MeDiet adherence score has commonly been used to 
enable a comparison between diets, whereby nine dietary compo-
nents are given a score of 0 or 1, with a score of 9 indicating maxi-
mum adherence [139]. A greater adherence to the MeDiet has been 
associated with a reduced incidence of overall mortality, cardiovas-
cular mortality, and/or cardiovascular events incidence; cancer mor-
tality and/or incidence; and incidence of Parkinson’s disease and 
AD [131].  
 A recent systematic review of longitudinal cohort studies exam-
ining the MeDiet effects on cognition outcomes found that higher 
adherence to the MeDiet was associated with a significant reduced 
risk of MCI and AD. Participants in the highest tertile of adherence 
to MeDiet had 33% less risk of MCI or AD when compared to 
those in the lowest tertile of adherence [129]. The RCT Predimed 
(Prevención con Dieta Mediterránea), which included adults aged 
55–80 years at high cardiovascular risk, showed that participants on 
a MeDiet supplemented with either extravirgin olive oil or nuts, had 
a reduced incidence of cardiovascular events compared to partici-
pants following a low-fat diet over the 5-year duration of the study 
[140]. PREDIMED was stopped before the expected time in the 
original design due to the evident benefit of the intervention arms 
with MeDiet. Two sub-analyses of samples of the PREDIMED 
RCT have recently reported that the dietary interventions with Me-
Diet supplemented with either extravirgin olive oil or nuts were 
associated with improved cognitive function when compared to a 
low-fat diet [141, 142].  
 A number of longitudinal population-based studies have exam-
ined the effects of adherence to the MeDiet on AD on cohorts from 
New York, US [143-147], and France [148, 149]. Two reviews 
[131, 150] assessing the cohort studies concluded that even if there 
is some evidence that adherence to the MeDiet is associated with a 
reduced risk of AD, further confirmation in populations with differ-
ent ethnicities and dietary habits is necessary. The results from two 
cohort studies from Australia have been published. The Personality 
and Total Health (PATH) through Life longitudinal study [151] of 
healthy participants found that MeDiet was not protective for cogni-
tive decline, while the Australian Imaging, Biomarkers and Life-
style (AIBL) study [152] reported that participants with AD and 
mild cognitive impairment had lower adherence to the MeDiet than 
healthy controls. A 7-year longitudinal study [136] examined if 
adherence to the HEI-2005 or to a MeDiet were associated with 
cognitive change in a cohort of 3,790 adults aged over 65 years 
from the ongoing Chicago Health and Aging Project longitudinal 
study. The results showed that compared to black participants, 
white participants had higher energy-adjusted MeDiet scores but  
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lower HEI-2005 scores. Following adjustments for different con-
founders, higher MeDiet scores were associated with slower rates 
of cognitive decline, but no association was found for HEI-2005 
scores. The MeDiet pattern also encompasses cultural and lifestyle 
elements such as social engagement, culinary activities, physical 
activity, and adequate rest [153]. These lifestyle factors, different 
from diet (exercise, social engagement, sleeping habits), have 
shown a positive influence on delaying cognitive decline; perhaps 
outcomes from MeDiet are due to lifestyle components, including 
dietary components, but not only attributable to diet. Future studies 
should consider all MeDiet lifestyle factors into their design. 
3.2. Okinawa Diet 
 The Okinawa diet is a low-calorie, nutrient-rich diet original 
from the Japanese Ryky Islands, of which Okinawa is the largest. 
The Okinawa diet has received attention over recent years because 
the residents of Okinawa were found to have some of the longest 
life expectancies and the highest concentration of centenarians in 
the world [154]. However, their life expectancy has fallen in recent 
years, probably because of less use of the traditional local diet and 
other genetic, lifestyle, and environmental factors. 
 The traditional Okinawa diet has eighty percent of calories from 
vegetable sources, whole grains, fruits, legumes (mainly soy), rela-
tively small amounts of fish, and limited amounts of lean meats 
[155]. The traditional Okinawa diet was twenty percent lower in 
calories compared to the Japanese average and contained a large 
proportion of colored vegetables (particularly sweet potatoes - Ipo-
moea batatas). Sweet potato, the carbohydrate source of Okinawa 
diet, is rich in antioxidants and has a low-glycemic index, while the 
Japanese diet takes carbohydrates from rice. Limited consumption 
of meat, eggs, and dairy products in the traditional Okinawan diet 
renders it low in saturated fats. 
 Albeit the effects of the Okinawa diet in relation to longevity 
have been studied in terms of caloric restriction and nutrient intake 
[155,156], there is still no solid evidence for the effects on preven-
tion of AD. A study examined the incidence of dementia in a small 
group of 157 older adults Japanese-Brazilians, aged 70 years and 
over, who emigrated from Okinawa to Campo Grande in Brazil 
[157]. The group had a 12.1% prevalence of dementia, while sev-
eral other Japanese communities, including a population of 2,217 
from Okinawa (evaluated in 1991), had a dementia prevalence of 
7.3%. The authors concluded that the dietary pattern modifications 
with low fish and high meat intake may be associated with in-
creases in dementia, rather than being due to genetic factors. The 9-
year difference between the studies and the small sample size of the 
Brazilian community compared to the Okinawa population may 
have affected the results on the different incidence of dementia. 
Another study compared circulating micronutrients concentrations 
from stored serum/plasma in a group of 115 participants from Ore-
gon, US, with 49 participants of an Okinawan group for possible 
associations with healthy cognitive aging [158]. Participants were 
aged 85 years and over without cognitive decline. Okinawan elders 
used fewer vitamin supplements but had similar levels of vitamin 
B12 and alpha-tocopherol, and lower folate and gamma-tocopherol 
when compared with elders from Oregon. There was no uniform 
protective micronutrient pattern between the two groups; hence, the 
authors concluded that micronutrients other than those examined, or 
other lifestyle factors, could play an important role in healthy cog-
nitive aging.  
3.3. Caloric Restriction  
 Although some population-based studies suggest an association 
of lower caloric intake with a lower risk of AD [159], older adults 
tend to have low nutrient intake especially those who progress to 
early-stage AD, when compared to cognitively intact controls 
[160]. AD patients frequently develop abnormal eating behaviors 
(i.e., anorexia nervosa, bulimia); hence, caloric restriction as a 
treatment for AD patients may be detrimental [159]. Nevertheless, 
caloric restriction has been associated with improved memory per-
formance in healthy older adults. A systematic review and meta-
analysis exploring the relationship between cognitive function and 
intentional weight loss in overweight and obese participants has 
been reported [161]. Twelve studies were included in the analyses 
showing variations in cognitive scores after significant weight loss. 
Participants’ age ranged from 20 to 80 years, with only one study of 
older participants (aged 50-80 years), and the majority of studies 
including younger participants (aged 40-60 years); study duration 
ranged from 28 days to 12.8 months, while the average body mass 
index (BMI) was 26.1 to 45.5 kg/m
2
. There was large heterogeneity 
among studies in duration, design, and neuropsychological tests. 
The meta-analysis random effects model for weight loss on memory 
performance showed significance, even though most studies 
showed non-significant results. This was attributable to the large 
sample size of one study and the greater effect size of another 
study. When studies considering exercise were excluded, the model 
became non-significant. The extent of the effect of weight loss on 
memory performance appeared directly associated with baseline 
BMI. For the attention and executive function domain, applied tests 
were non homogeneous across studies; however, meta-analysis 
showed significance, and the exclusion of studies with exercise or 
bariatric surgery did not change the results. As with memory per-
formance, the extent of weight loss effect on attention and execu-
tive function was directly associated with baseline BMI. Cognitive 
function was assessed immediately after weight loss; hence, the 
stability of improved cognitive function needs further investigation, 
as do the effects of metabolic and body composition modifications 
on cognitive performance. The effects of intentional weight loss on 
the physical and cognitive function of 50 obese aged 30–59 years 
and older participants (over 60 years) were examined in a pilot 
study [162]. The average weight loss of the 21 participants was 
about 10% of initial body weight, and weight loss was associated 
with improved hand-grip strength and cognitive function, with a 
significant increase in the MMSE scores in older obese participants. 
 A confounding factor in animal studies is that caloric restriction 
result in an overall increase in physical activity [163]. This factor 
might be considered in future human trials evaluating the effects of 
caloric restriction in delaying the onset of AD. Okinawa diet has 
been recognized as a caloric-restrictive diet [155, 156]. Some of the 
MeDiet populations traditionally use fasting for religious occasions; 
hence, there may be synergistic effects of caloric restriction with 
MeDiet, but this would need to be explored in future RCTs. Life-
style and nutritional factors, including exercise and caloric restric-
tion, are proposed to exert their health benefits through autophagy 
pathways [164]. 
3.4. Vegetarian Diets 
 In general, vegetarian diets are adopted following ethical, 
health, environmental, religious, political, cultural, esthetic, eco-
nomic, and culinary influences. Vegetarian diets are mostly plant-
based diets including fruits, vegetables, cereal grains, nuts, and 
seeds; mushrooms; with or without dairy products; and eggs. There 
are several variations of the vegetarian diet, but all avoid red meat 
consumption. A total vegetarian does not eat all kinds of meat and 
may also abstain from by-products of animal slaughter (i.e. rennet 
and gelatin). The first Adventist Health Study project was con-
ducted from 1974 to 1988 with a population of devotees of the Sev-
enth-day Adventist church. The incidence of dementia in those 
consuming vegetarian diets and meat-eating diets was compared in 
two cohort sub-studies in groups aged 65 years and over [165]. The 
first study of 272 California residents matched for age, sex, and 
living locality included vegan, ovo-lacto-vegetarian, versus two 
high-meat-eating groups; the results showed that subjects who ate 
meat (i.e., poultry and fish) were more than twice as likely to be-
come demented as their vegetarian counterparts (RR 2.18), and this 
was more prominent (RR 2.99) when past meat consumption was 
8    Current Pharmaceutical Design, 2016, Vol. 22, No. 00 Dominguez and Barbagallo 
considered. Another analysis of a group of 2,984 unmatched par-
ticipants showed no significant difference in the incidence of de-
mentia between vegetarian and meat-eating subjects, with no clear 
explanation for the difference between the two sub-studies. Al-
though the authors reported a trend toward delayed onset of demen-
tia in vegetarians in both studies, there was no clear evidence that 
any standardized cognitive assessment was used to assess partici-
pants during the study.  
3.5. Ketogenic Diet 
 The ketogenic diet (KD) has been associated with neuroprotec-
tive effects in some forms of epilepsy, and its effects in neurode-
generative disorders including AD have been recently investigated 
[166]. The KD is a high-fat (predominantly saturated), low-
carbohydrate, adequate protein diet, which is used to treat refractory 
epilepsy in children. Dietary carbohydrates are converted into glu-
cose, which is a particularly important fuel for brain function. The 
KD mimics starvation by forcing the body to burn fats rather than 
carbohydrates. If the diet is low in carbohydrates, the liver converts 
fat into fatty acids and ketone bodies (beta-hydroxybutyrate, ace-
toacetate, and acetone), which enter into the brain and replace glu-
cose as an energy source. The attained state of ketosis leads to a 
reduction in the frequency of epileptic seizures [167]. The classic 
ratio by weight of fat over combined protein and carbohydrate in 
KD is 4:1. While there is no current evidence of AD prevention 
with KD, a small double-blind placebo-controlled study of 20 pa-
tients with MCI or AD showed memory scores improvement in 
patients receiving medium-chain triglycerides in order to elevate 
plasma ketone bodies concentrations [168]. The study found im-
provements in memory scores in non-APOE 4 patients but not in 
APOE 4 positive patients. A possible explanation of the results is 
that brain glucose metabolism is impaired in AD, while ketone 
bodies may provide an alternative energy source. A clinical trial of 
152 participants reported similar results [169]. A recent review 
[170] has underlined some of the possible metabolic mechanisms of 
the KD, including, decreasing beta-amyloid accumulation and al-
tered mitochondrial function, as well as protection against the neu-
rotoxicity of beta-amyloid, which may result in reduced oxidative 
stress and neuroinflammation. However, many of the findings with 
KD come from animal studies and a solid validation in human trials 
is still warranted. 
 High-fat diets, particularly high in saturated fats, are potentially 
detrimental as mentioned above [32, 33]. Therefore, this may be in 
contrast with the potential benefit of ketone bodies. A study tested 
the effects of two high-fat diets, one rich in PUFA vs. a diet rich in 
SFA on serum beta-hydroxybutyrate, insulin sensitivity, and lipid 
profiles in twenty healthy adults. The PUFA-rich diet induced a 
greater level of ketosis and was associated with improvement in 
insulin sensitivity, without altering low-density cholesterol, com-
pared to SFA-rich diet [171]. 
3.6. Low-Copper Diet 
 Copper (Cu) is an essential element in the body. Even if plasma 
copper (Cu) levels relates to Cu intake with diet, the origin of free 
Cu is still under discussion, potentially depending on inflammation 
status. There is recent evidence indicating that altered Cu metabo-
lism may be one of the pathogenic mechanisms of AD and other 
neurodegenerative diseases [172]. A longitudinal study involving 
3,718 participants showed that high intakes of copper, mostly from 
copper supplements, in combination with a high-fat diet resulted in 
more rapid cognitive decline in the general population after 5.5 
years follow-up [173]. Conversely, in a study of 32 patients with 
mild to moderate AD, despite the fact that all patients had Cu levels 
in the physiological range (65-165 mcg/dL), patients with low 
plasma Cu had significantly higher ADAS-cog scores [174]. This is 
important because the general population is frequently in contact 
with Cu, and the promotion of a low-Cu diet may potentially reduce 
the risk of AD [175]. However, there is no conclusive evidence that 
depletion or supplementation of Cu may modify AD incidence or 
pathology. Post-mortem studies reported decreased or unchanged 
levels of Cu in the hippocampus, cerebellum, cortex, or amygdala 
in patients with AD when compared to controls [176]. Further re-
search is certainly needed to define the role of Cu homeostasis in 
the brain during AD, but until then it is wise to advise o low dietary 
intake of Cu, including drinking water, and avoidance of Cu sup-
plements, regardless of the current lack of consistent data.  
3.7. Dietary Approaches to Stop Hypertension (DASH) 
 This is a dietary balanced eating plan, rich in fruits, vegetable, 
and low-fat dairy, with reduced total fats and sugar-sweetened 
products, which effectively lowers blood pressure, improves lipid 
profiles, and reduces incident cardiovascular events [177]. Al-
though DASH was not specifically design to influence cognitive 
function, its positive effects on vascular health may be neuroprotec-
tive. 
 A recent study investigated the associations between DASH and 
MeDiet adherence with age-related cognitive changes prospectively 
in 3,831 participants older than 65 years residents of Cache County, 
UT, followed for over 11 years. Higher adherence to DASH and 
MeDiet and higher consumption of whole grains, nuts and legumes 
were significantly associated with higher average scores of modi-
fied MMSE after follow-up [178]. A recent study reported similar 
findings combining the two dietary patterns (MeDiet-DASH, or 
MIND), following a cohort of 960 participants of the Memory and 
Aging Project for a mean of 4.7 years. After adjusting for con-
founders, the MIND score was positively associated with slower 
decline in global cognitive score and with five single cognitive 
domains. The differences in decline rates for those at the highest 
tertile of MIND adherence score vs. the lowest tertile was equiva-
lent to being 7.5 years younger in age [179]. The same group of 
researchers examined the effects of the hybrid diet on incident AD 
in 923 participants, aged 58-98 years, followed on average 4.5 
years. Adjusted proportional hazards models showed significant 
reduction in incident AD for the second and third tertile of adher-
ence scores to MIND diet vs. the lowest tertile, whereas only the 
third tertiles of DASH and MeDiet were associated with lower AD 
rates. Therefore, both patterns are protective but the highest the 
adherence to both (or MIND diet), the better the prevention of AD 
[180]. Replications of these results with DASH and MIND are re-
quired to verify their relevance to brain health. 
3.8. Paleolithic Diet 
 The Paleolithic diet is also called the hunter-gatherer diet, an-
cestral diet, primal diet, evolutionary diet, and caveman diet. This 
diet is based on foods that were eaten prior to agriculture and ani-
mal farming (e.g., meat, fish, shellfish, eggs, tree nuts, vegetables, 
roots, fruit, berries, mushrooms) during the Paleolithic Era, exclud-
ing foods resulting from agriculture or animal farming (grains, 
dairy, beans/legumes, potatoes, sugar, meats, and manufactured 
foods). Food consumption was based on availability in a specific 
location as part of a nomadic lifestyle; hence diets could vary con-
siderably from season to season. A recent systematic review of four 
RCTs involving 159 participants found that the Paleolithic diet 
resulted in greater short-term improvements on metabolic syndrome 
components compared to guideline-based control diets [181]. A 
study of 20 overweight postmenopausal women compared the ef-
fects of a 6-month modified Paleolithic diet vs. a standard diet fol-
lowing the Nordic Nutrition Recommendations on parameters of 
functional MRI with episodic memory tasks, and weight loss. There 
was a significant improvement in episodic memory performance 
after the dietary interventions, without differences between diets, 
which was associated with increased hippocampal activity, de-
creased waist circumference, and reduced plasma FFA [182]. There 
are still no studies on the effects of a Paleolithic diet and the pre-
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vention of AD, despite the higher frequency of distribution of the 
APOE 4 allele in many of the hunter-gatherer populations cur-
rently living around the world [183]. However, the available data 
warrant additional evaluations of the brain health benefits of Paleo-
lithic nutrition. 
CONCLUSION 
 While there seems to be no significant benefit in preventing 
further cognitive decline with nutritional interventions for patients 
with established dementia or AD, research on the potential of nutri-
tional interventions to prevent or delay cognitive impairment and 
the development of AD is rapidly growing, with various clinical 
trials recently being completed or underway. Results from large-
scale epidemiologic studies and clinical trials generally do not sup-
port a clear role for most of the nutritional and dietary factors that 
have been examined for prevention of cognitive decline or AD. It is 
reasonable to conclude that the influence of dietary supplementa-
tion on cognitive function in healthy middle-aged and older adults 
and in those with cognitive decline or AD remains at best uncertain, 
and further research is warranted to clarify the benefits of these 
approaches.  
 The role of the Mediterranean diet in cardiovascular health is 
well established, and there is moderately convincing evidence pri-
marily from population/epidemiologic studies (the number of stud-
ies is still small) that adherence to this dietary pattern is associated 
with a reduced risk of AD; however, further confirmation in pro-
spective study populations and RCTs with longer follow-up, with 
different ethnicities and different dietary habits is warranted, as 
well. There is currently no evidence to validate any effects of the 
vegetarian, Okinawa, ketogenic, Paleolithic or caloric restriction 
diets on the prevention of cognitive decline or AD. 
 The literature is beginning to emphasize the importance of 
studying dietary patterns or whole of diet approaches rather than 
individual foods or nutrients due to likely synergistic effects of 
nutrient combinations. For example, a dietary pattern high in satu-
rated fatty acids but also high in monounsaturated fatty acids may 
result in an overall null effect. Hence, studying dietary patterns and 
evaluating food combinations may provide insights into synergistic 
actions of some nutrient combinations with respect to delaying the 
onset of cognitive decline and dementia. 
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